Resources Repository
-
ArticlePublication 2021Correct COVID-19 Vaccine Misinformation: Lancet Commission on COVID-19 Vaccines & Therapeutics Task Force Members
This brief “primer” assists healthcare providers in correcting a growing body of misinformation surrounding COVID-19 …
This brief “primer” assists healthcare providers in correcting a growing body of misinformation surrounding COVID-19 vaccines. In 2020, up to one-third or more of people surveyed both globally and in the U.S. indicated they might refuse the first COVID-19 vaccines when released through emergency use authorization (EUA). Their rationale included questions about vaccine efficacy, potential side effects, or speeding through regulatory approval processes. Even among healthcare workers, high rates of COVID-19 vaccine hesitancy were noted.…
Preferences/Values | Policy/Regulation | Infectious Diseases | Social Determinants | Global Governance | Culture/Society | Health/Medicine | Science/Technology | Global -
ArticlePublication 2020Testing for SARS-CoV-2 Antibodies
Antibody testing can determine previous exposure to SARS-CoV-2 virus. Recently, the UK government has made …
Antibody testing can determine previous exposure to SARS-CoV-2 virus. Recently, the UK government has made antibody testing available to anyone wanting it, even if there is no clinical indication. The purpose of this article is to provide guidance for when to consider antibody testing in individuals with and without symptoms suggestive of current or past SARS-CoV-2 infection. Key points made by the authors include: (1) antibody testing is likely to be most useful 2 weeks…
Probability/Bayes | Clinical Care | Test Performance | Technology Assessment | Infectious Diseases | Health/Medicine -
ArticlePublication 2021Health Opportunity Cost Threshold for CEA in the U.S.
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, …
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, the authors simulated the short-term mortality and morbidity resulting from increased premium related cancelation of insurance coverage. The authors used this model to estimate cost-effectiveness thresholds, in dollars per quality-adjusted life year (QALY) gained based on health opportunity costs. They reported the number of persons who dropped insurance coverage, resulting number of additional deaths and QALYs lost from mortality and…
Priority Setting/Ethics | Policy/Regulation | Health Outcomes | Evidence Synthesis | Microsimulation | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | North America -
ArticlePublication 2020Bayes' Theorem, COVID-19, and Screening Tests
This article reviews the implications of increased testing for COVID-19 using reverse transcriptase polymerase chain …
This article reviews the implications of increased testing for COVID-19 using reverse transcriptase polymerase chain reaction (rRT-PCR) through the application of Bayes’ Theorem for three hypothetical, stylized case scenarios. The scenarios involve three patients with a low, moderate, and high pre-test probability of COVID-19 infection. The category of low probability would include "asymptomatic individuals in a presumed low prevalence environment" and might vary from 10 to 20%. The category of moderate probability would include "individuals…
Probability/Bayes | Clinical Care | Test Performance | Infectious Diseases | Health/Medicine -
ArticlePublication 2020Weighing Evidence to Inform Clinical Decisions
The authors use a clinical example to simulate how treatment discussions can be complicated when new evidence is introduced …
The authors use a clinical example to simulate how treatment discussions can be complicated when new evidence is introduced that conflicts with existing guidelines. Even when evidence is consistent, the authors point out that current guidelines can have interpretations that don't agree with available evidence. They develop a step-wise algorithm to help guide individual clinical decisions even in the absence of general consensus related to appropriate testing and treatment.
Priority Setting/Ethics | Clinical Care | Evidence Synthesis | Health/Medicine -
ArticlePublication 2020Clinical Decision Making: Using a Diagnostic Test
This article is part of a 6-part series on clinical decision making. The authors use …
This article is part of a 6-part series on clinical decision making. The authors use two clinical examples to review the principles of interpreting diagnostic test results. They outline an approach that can be used to determine how to select and apply tests and their results to the practice of internal medicine. Topics covered in the two case studies include sensitivity and specificity, positive predictive and negative predictive value of tests, and how to estimate…
Probability/Bayes | Clinical Care | Test Performance | Health/Medicine -
ArticlePublication 2020Who Benefits Most from Extending Financial Protection for Cataract Surgery in Vietnam?: An ECEA
This study evaluated the potential impact, on health and financial protection, of eliminating medical and …
This study evaluated the potential impact, on health and financial protection, of eliminating medical and non-medical out-of-pocket costs associated with cataract surgery in Vietnam using extended cost-effectiveness analysis.
Priority Setting/Ethics | Chronic Disease/Risk | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Health/Medicine | Asia & Pacific -
ArticlePublication 2020Premature Deaths, Statistical Lives, and Years of Life
This article clarifies some misconceptions about mortality risk and economic valuation. The mortality effects of …
This article clarifies some misconceptions about mortality risk and economic valuation. The mortality effects of exposure to environmental hazards such as air pollution are often described by the estimated number of “premature deaths” and the economic value of an exposure reduction as the number of “statistical lives saved” multiplied by the “value per statistical life.” These terms can be misleading because the number of deaths advanced by exposure cannot be determined from mortality data; it…
Preferences/Values | Policy/Regulation | Health Outcomes | Benefit-Cost Analysis | Environmental Health | College | Graduate | Critical Thinking/Analysis -
ArticlePublication 2016Health and Economic Benefits of Public Financing of Epilepsy Treatment in India
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of …
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of publicly financed national epilepsy programs in India that provide (1) first line antiepilepsy drugs (AEDs), (2) first- and second-line AEDs, and (3) first- and second-line AEDs and surgery. Outcome measures include disability-adjusted life years (DALYs) averted, and cost per DALY averted. Economic benefit measures estimated include out-of-pocket (OOP) expenditure averted and money-metric value of insurance. All three scenarios represent a…
Priority Setting/Ethics | Chronic Disease/Risk | Microsimulation | Cost-Effectiveness Analysis | Economics/Finance | Health/Medicine | Asia & Pacific